Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study, PMID: 31859245
Belantamab Mafodotin: First Approval, PMID: 32936437
Belantamab Mafodotin-blmf, PMID: 32959867
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma, PMID: 33179377
Belantamab Mafodotin, PMID: 32816421
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study, PMID: 32712806
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study, PMID: 33097687
Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma, PMID: 32875817
Antibodies to watch in 2020, PMID: 31847708
BCMA-targeted immunotherapy for multiple myeloma, PMID: 32943087
The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma, PMID: 33403093
Belantamab Mafotodin-Induced Epithelial Keratopathy Masquerading Myopic Surgery, PMID: 33222774
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches, PMID: 32055000
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety, PMID: 34103900
Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients, PMID: 33306485
Bispecifics, trispecifics, and other novel immune treatments in myeloma, PMID: 33275733
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects, PMID: 33494319
B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma, PMID: 32707894
How I treat relapsed and/or refractory multiple myeloma, PMID: 33042504
Belantamab mafodotin detection by MASS-FIX and immunofixation, PMID: 34114387
[Iatrogenic keratopathy secondary to multiple myeloma treatment with belantamab mafodotin], PMID: 33454122
Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial, PMID: 32107339
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma, PMID: 34046363
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor, PMID: 34434061
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial, PMID: 30442502
Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma, PMID: 34234609
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study, PMID: 32920777
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design, PMID: 33682447
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study, PMID: 30894515
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-Mediated Anti-Tumor Responses In Vivo, PMID: 34253590
Anti-BCMA Therapy Endorsed, despite Eye Toxicity, PMID: 32759303
Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma, PMID: 34076364
[Multiple myeloma: a focus on drugs under development], PMID: 32507818
Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography, PMID: 34169181
Antibody-drug conjugates for multiple myeloma, PMID: 32729730
Hitting a New Target in Multiple Myeloma, PMID: 33206990
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM), PMID: 34039952
[New treatments present new challenges : Ocular side effects of belantamab mafodotin], PMID: 33978807
Uveal effusion syndrome secondary to belantamab mafodotin in a patient treated for refractory myeloma, PMID: 34384623
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study, PMID: 34314018
Current antibody-based therapies for the treatment of multiple myeloma, PMID: 33406065
Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021, PMID: 33216972
Current developments in the combination therapy of relapsed/refractory multiple myeloma, PMID: 32969752
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes, PMID: 33291602
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma, PMID: 33896344
Update on the Treatment of Heavily Pretreated, Relapsed Refractory Multiple Myeloma, PMID: 33206992
[Multiple myeloma-soon curable?], PMID: 33783581
Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses, PMID: 32153224
An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma, PMID: 33412948
Rethinking mechanisms of neurotoxicity with BCMA directed therapy, PMID: 34461271
An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma., PMID:40507995
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of belantamab mafodotin for multiple myeloma, asciminib for leukemia, osimertinib for lung cancer, amivantamab for lung cancer, and pembrolizumab for pleural mesothelioma in Japan., PMID:40481943
Real-world characteristics and outcomes of patients with multiple myeloma treated with belantamab mafodotin: a German claims data study., PMID:40448822
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma., PMID:40447948
Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting., PMID:40361170
Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis., PMID:40348718
Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma., PMID:40338596
Corneal Findings in Patients Treated with Belantamab Mafodotin: A Prospective Case Series Focusing on Corneal Nerves., PMID:40327294
Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland., PMID:40308262
HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin., PMID:40154473
HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin., PMID:40154424
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis., PMID:40143674
Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development., PMID:40140348
Current Treatment Strategies for Multiple Myeloma at First Relapse., PMID:40095642
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System., PMID:40095047
Novelties on Multiple Myeloma from the Main 2024 Hematology Conferences., PMID:40084104
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma., PMID:40064854
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma., PMID:39938011
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development., PMID:39920159
Novel Treatment Options for Multiple Myeloma., PMID:39772633
Update on B-cell maturation antigen-directed therapies in AL amyloidosis., PMID:39748220
DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma., PMID:39718747
The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review., PMID:39664714
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis., PMID:39653116
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation., PMID:39505212
Focal and Segmental Glomerulosclerosis in a Multiple Myeloma Patient After Belantamab Mafodotin Therapy and Severe COVID-19 Infection: A Case Report., PMID:39482831
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System., PMID:39458907
Strengths and Weaknesses of Different Therapeutic Strategies for the Treatment of Patients with Multiple Myeloma Who Progress After the Frontline Use of Lenalidomide: A Narrative Review., PMID:39458188
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma., PMID:39433730
Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States., PMID:39415693
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. Reply., PMID:39383466
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma., PMID:39383465
Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature., PMID:39357511
Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma., PMID:39292169
Drug-Related Keratitis: A Real-World FDA Adverse Event Reporting System Database Study., PMID:39287587
How to rescue a DreaMM deferred …., PMID:39276768
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial., PMID:39261451
Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)., PMID:39228525
Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma., PMID:39226081
The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease., PMID:39204135
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma-a case report., PMID:39112495
A Belantamab Mafodotin Revival in Multiple Myeloma Therapy., PMID:39083777
Belantamab-mafodotin-associated keratopathy., PMID:39003154
Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?, PMID:38976493
Belantamab mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and -2 studies., PMID:38924122
Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma., PMID:38900711
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy., PMID:38895069
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease., PMID:38850573
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma., PMID:38828951
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma., PMID:38828933
For research use only. Not for human or drug use.
